MicardisPlus 80 mg/12.5 mg tablets

  • Name:

    MicardisPlus 80 mg/12.5 mg tablets

  • Company:
    info
  • Active Ingredients:

    Hydrochlorothiazide, Telmisartan

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 20/12/18

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 18/12/2018

Click on this link to Download PDF directly

Boehringer Ingelheim Limited

Boehringer Ingelheim Limited

Company Products

Medicine NameActive Ingredients
Medicine Name Actilyse Active Ingredients Alteplase
Medicine Name Actilyse Cathflo 2 mg Active Ingredients Alteplase
Medicine Name APTIVUS 100 mg/ml oral solution Active Ingredients Tipranavir
Medicine Name Aptivus 250 mg soft capsules Active Ingredients Tipranavir
Medicine Name Atrovent 250 UDVs, 250 micrograms/1ml Nebuliser Solution Active Ingredients ipratropium bromide monohydrate
Medicine Name Atrovent 500 UDVs, 500 micrograms/2ml Nebuliser Solution Active Ingredients ipratropium bromide monohydrate
Medicine Name Atrovent Inhaler CFC-Free Active Ingredients ipratropium bromide monohydrate
Medicine Name Catapres Ampoules Active Ingredients Clonidine hydrochloride
Medicine Name Catapres Tablets 100 micrograms Active Ingredients Clonidine hydrochloride
Medicine Name Giotrif 20 mg film-coated tablets Active Ingredients Afatinib dimaleate
Medicine Name Giotrif 30 mg film-coated tablets Active Ingredients Afatinib dimaleate
Medicine Name Giotrif 40 mg film-coated tablets Active Ingredients Afatinib dimaleate
Medicine Name Giotrif 50 mg film-coated tablets Active Ingredients Afatinib dimaleate
Medicine Name Glyxambi 10 mg/5 mg film-coated tablets Active Ingredients Empagliflozin, Linagliptin
Medicine Name Glyxambi 25 mg/5 mg film-coated tablets Active Ingredients Empagliflozin, Linagliptin
Medicine Name Jardiance 10 mg and 25 mg Film-Coated Tablets Active Ingredients Empagliflozin
Medicine Name Jentadueto 2.5 mg/850 mg film-coated tablets and Jentadueto 2.5 mg/1,000 mg film-coated tablets Active Ingredients Linagliptin, Metformin Hydrochloride
Medicine Name Metalyse 10,000 units Active Ingredients Tenecteplase
Medicine Name Metalyse 8,000 units Active Ingredients Tenecteplase
Medicine Name Micardis 20 mg Tablets Active Ingredients Telmisartan
Medicine Name Micardis 40 mg Tablets Active Ingredients Telmisartan
Medicine Name Micardis 80 mg Tablets Active Ingredients Telmisartan
Medicine Name MicardisPlus 40 mg/12.5 mg tablets Active Ingredients Hydrochlorothiazide, Telmisartan
Medicine Name MicardisPlus 80 mg/12.5 mg tablets Active Ingredients Hydrochlorothiazide, Telmisartan
Medicine Name MicardisPlus 80 mg/25 mg Active Ingredients Hydrochlorothiazide, Telmisartan
1 - 0 of 50 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 20 December 2018 PIL

Reasons for updating

  • Change to section 6 - date of revision

Updated on 18 December 2018 SmPC

Reasons for updating

  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

The only update to the previous versions, implemented on 04 December 2018, is to section 10 date of revision

Updated on 6 December 2018 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect
  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision
  • Correction of spelling/typing errors

Updated on 5 December 2018 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text
  • Correction of spelling/typing errors

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Sections 4.4, 4.8 and 5.1 of the SmPCs have been updated. In addition a minor editorial update has been made to the section 4.8 AE reporting details. A minor correction has also been made to the SmPC title for the 40 mg/12.5 mg and 80 mg/12/5 mg tablets.

Section 10, date of revision of the text has been updated

Updated on 11 July 2018 PIL

Reasons for updating

  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision
  • Change to other sources of information section

Updated on 10 July 2018 SmPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 9 - Date of first authorisation/renewal of the authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 10 August 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 10 August 2017 PIL

Reasons for updating

  • Improved presentation of PIL

Updated on 1 June 2017 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 3 - how to take/use
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision
  • Change to other sources of information section

Updated on 30 May 2017 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text
  • Change from individual to joint SPC

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

-Sections 1, 2, 3, 4.1, 8 updated as a result of merging the 40/12.5 mg and 80 mg/12.5 mg SPCs

-Sections updated in line with CCDS 0252-11  4.2, 4.4, 4.5, 4.7, 4.8, 5.1, 5.2, 6.6.

 

4.2, 4.5, 4.8, 5.1 (Clarification of sub-headings and minor editorial clarifications)

4.4 (update to contraindication for  patients with severe renal impairment)

4.5 (Detail added regarding interactions with Calcium salts)

4.7 (Clarification of instructions on driving and use machines)

4.8 (Hydrochlorothiazide adverse reactions frequencies revised for: Thrombocytopenia, hypomagnesaemia, hypercalcaemia, hypochloraemic alkalosis, headache, nausea, erythema multiforme)

5.1 (Section rearranged with revised sub-headings)

Paediatric population detail added

5.2 (Details regarding Linearity/non-linearity updated)

6.6 (Updated disposal instructions)

 


-Section 4.8 was updated to include the  revised adverse drug reaction reporting Maltese address.

-Sections 2 Typographical change

-Section 10 revision date updated in line with PO (06Apr17).

Updated on 30 May 2017 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 3 October 2016 PIL

Reasons for updating

  • Change of contraindications
  • Change to instructions about overdose
  • Change to side-effects
  • Change to information about drinking alcohol
  • Change to date of revision
  • Addition of information on reporting a side effect.

Updated on 24 September 2014 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

The SPCs have been updated to been revised to take into account the updated wording for concomitant use with ARBs or aliskiren in the contraindication, warning and interactions section of SPC following conclusion of the EU Art 31 Referral Procedure on RAS acting agents – class labelling request (ref EMEA-H-A-31-1370).  Date of EC decision is 4 September 2014 with final text being available 10 September. Sections affected are 4.2, 4.3, 4.4, 4.5 also with revision to 5.1. In addition, in section 4.8 the Irish Authority contact details for Adverse Event reporting have been revised following the recent authority name change. Date of revision has also been updated to September 2014.

 

Further to the above, an error has been corrected within Section 4.8 regarding the frequency of hyperkalaemia together with an additional minor/editorial update. These changes were made to align with the final approved texts and impact the 40/12.5 mg and 80/12.5 mg strength only.

Updated on 24 September 2014 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change of contraindications
  • Change to date of revision
  • Addition of information on reporting a side effect.

Updated on 4 December 2013 PIL

Reasons for updating

  • Change to further information section
  • Change to date of revision
  • Addition of information on reporting a side effect.

Updated on 4 December 2013 SmPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.8 Undesirable Effects

New text regarding the reporting of suspected adverse reactions in the UK, Ireland and Malta has been added at the end of this section.  In total, four new paragraphs have been added.

 

Section 5.1 Pharmacodynamic Properties

A new sub-heading (and corresponding text) regarding Cardiovascular prevention has been added to this section.  In total, 7 new paragraphs have been added.

 

The previous text of The effects of telmisartan on mortality and cardiovascular morbidity are currently unknown has been deleted from this section.  The text was previously located between the In the “Prevention Regimen for Effectively avoiding Second Strokes” … and Hydrochlorothiazide is a thiazide diuretic … paragraphs.

 

Section 10 Date of Revision of the Text

The date has been amended from May 2013 to October 2013.

 

Updated on 26 June 2013 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change of contraindications
  • Change to storage instructions
  • Change to side-effects
  • Change to drug interactions
  • Change to further information section
  • Change to date of revision

Updated on 21 June 2013 SmPC

Reasons for updating

  • Addition of separate SPCs covering individual presentations

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

None provided

Updated on 11 July 2012 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change of contraindications
  • Change to storage instructions
  • Change to side-effects
  • Change to drug interactions
  • Change to information about pregnancy or lactation
  • Change to information about driving or using machinery
  • Change to further information section
  • Change to date of revision
  • Change to dosage and administration
  • Change to MA holder contact details

Updated on 15 February 2012 PIL

Reasons for updating

  • Change of manufacturer
  • Change to date of revision

Updated on 19 July 2011 PIL

Reasons for updating

  • Change to MA holder contact details
  • Change to name of manufacturer

Updated on 8 May 2010 PIL

Reasons for updating

  • Change to side-effects

Updated on 9 June 2009 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 22 August 2008 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 11 September 2007 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 12 June 2006 PIL

Reasons for updating

  • New PIL for medicines.ie